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1. Introduction 
Animal models serve as important tools for preclinical testing of therapeutic regimens 
against human immunodeficiency virus (HIV-1), the primary etiologic agent that causes 
acquired immunodeficiency syndrome (AIDS). Infection and treatment of patients often 
cannot be controlled in clinical studies. In addition, performing certain procedures and 
sampling cannot be routinely performed in humans with ease and may be unethical. There 
are many different primate and murine models of HIV/AIDS, each with their advantages 
and disadvantages. Some models are appropriate in certain contexts but not others. 
Knowing how the different models work and their limitations will help guide the researcher 
to select the appropriate model to answer a specific question. Information gained from the 
use of preclinical testing of antiretroviral therapies will help identify and improve 
preventive, therapeutic, and eradication strategies against HIV/AIDS in humans. 
2. HIV-1 infection of nonhuman primates or humanized mice: Which is the 
better model to use? 
An animal model for human disease should mimic the infection of humans as closely as 
possible. The disease course in the model should be similar to or more accelerated than in 
humans. In the case of HIV-1, an animal model that progresses to AIDS over the period of 
many years will cost time and money in preclinical studies. The use of animals instead of 
humans usually means certain procedures can be performed more easily and/or ethically. 
For example, removing vital organs to study pathogenesis, drug penetration, immunity, or 
virology cannot be performed in humans but can be done after necropsy of an animal. 
Moreover, unlike in humans, the exact virus, timing of infection, and timing of treatment 
can be controlled in a model. 
HIV-1 does not efficiently replicate in most animals, including nonhuman primates. This is 
due to differences in host cell factors present in different species that are required for 
infection or due to innate immunity that appears to have evolved in mammals to ward off 
infections. Thus, either modification to HIV-1 or to the animal must be made for significant 
viral replication to occur. This is important for assessing the efficacy of experimental 
interventions for inhibiting the virus rather than spontaneous control by the host immune 
system. 
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2.1 Nonhuman primate models 
Nonhuman primates are genetically and anatomically most similar to humans and would be 
the obvious choice for an animal model to study HIV-1. While HIV-1 is believed to have 
arisen from cross-species transmission of simian immunodeficiency virus (SIV) strains from 
chimpanzees and gorillas to humans (Keele et al., 2006; Van Heuverswyn et al., 2006), these 
animals are not routinely used for HIV research. These great apes are both endangered and 
very large. And although HIV-1 has been used in the past to infect chimpanzees in captivity, 
it does not cause significant disease for more than a decade (Novembre et al., 1997). Thus, 
this is an impractical model for testing treatments and vaccines against the virus.  
Macaques, a genus of Old World monkeys, are routinely bred at primate centers and have 
been extensively investigated as HIV models. HIV-1 inoculation of macaques does not lead 
to productive infection, mainly due to restriction by simian innate immune factors, such as 
APOBEC3G and TRIM5, that target HIV-1 (Mariani et al., 2003; Stremlau et al., 2004). SIV 
is a primate lentivirus that is similar to HIV-1 and highly homologous to HIV type 2 (HIV-
2), which was isolated from rhesus macaques at a primate facility (Daniel et al., 1985; Kanki 
et al., 1985). SIV infection of macaques is believed to have been another cross-species 
transmission during captivity from infected African primates (Hirsch et al., 1989), leading to 
pathogenesis similar to AIDS but in a more accelerated time frame as compared to HIV-1 
infection of humans. In addition, adaptive immune responses against SIV in macaques are 
similar to anti-HIV-1 responses seen in humans (Sato and Johnson, 2007; Valentine and 
Watkins, 2008). The most widely used species of macaques for HIV/AIDS models are rhesus 
(Macaca mulatta), cynomolgus (M. fasicularis), and pigtailed (M. nemestrina). 
While SIV shares high structural and sequence identity to HIV-1, the differences are 
significant enough to limit the design of both vaccines and therapy against the human virus. 
Therefore, HIV-1 sequences have been added into the SIV genome to make chimeric viruses, 
called SHIVs, which can still replicate well within macaques (Fig. 1). The first examples of 
SHIVs were SIV strains that encoded HIV-1 envelope in place of SIV envelope, such that 
vaccines or drugs could target this entry protein (Li et al., 1992; Luciw et al., 1995; Reimann 
et al., 1996; Shibata et al., 1991). More recently, the reverse transcriptase (RT) coding region 
of SIVs have been replaced with that of HIV-1 to produce RT-SHIV that can be targeted by 
RT inhibitors (Ambrose et al., 2004; Uberla et al., 1995). Both types of SHIVs have been 
shown to infect macaques after mucosal exposure, simulating sexual transmission (Lu et al., 
1996; Turville et al., 2008). Simian-tropic HIV-1 (stHIV-1) viruses have been made that 
contain minimal SIV sequences (capsid and Vif coding regions) to circumvent restriction 
from APOBEC3G and TRIM5, but they suffered significant decreases in replication in the 
host compared to SIV or the previously described SHIVs, likely due to differences in the 
accessory proteins of HIV-1 as compared to SIV (Hatziioannou et al., 2009; Igarashi et al., 
2007).  
Baboons and other species of Old World monkeys have also been used as nonhuman primate 
models for studying HIV infection and AIDS. Baboons could be productively infected with 
HIV-2 but showed little pathogenesis (Barnett et al., 1994). African green monkeys and sooty 
mangabeys are naturally infected with SIV but do not experience disease despite very high 
levels of viremia. These animals are studied for their differences to Asian macaques to 
understand chronic, pathogenic SIV/HIV infection (Paiardini et al., 2009). 
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Fig. 1. Diagram of the genomes of HIV-1, SIV, and chimeric viruses used in macaques. White 
color denotes HIV-1 sequences, while gray shading denotes SIV sequences. 
2.2 Humanized mouse models 
The strengths of murine models for biomedical research are the small size of mice and their 
relatively low cost, making it feasible to have increased numbers of animals in experiments 
for greater statistical power. However, HIV-1 encounters multiple barriers in the infection of 
mouse cells, beginning with the inability of the virus to use the murine CD4 receptor and co-
receptors. To overcome these issues, scientists reconstituted a partial human immune 
system in severe combined immunodeficient (SCID) mice lacking lymphocytes by 
engrafting them with human peripheral blood lymphocytes or human fetal thymus and 
liver (Mosier et al., 1988; Namikawa et al., 1990). However, while peripheral T cell subsets 
could be reconstituted temporarily in these SCID-hu mice, they were not detected to a great 
extent in tissues. In addition, other human immune cells did not develop and only transient 
HIV-1 replication could be detected in vivo. 
Due to the limitations of SCID-hu mice, new advances in humanized murine models have 
been made to better reconstitute a human immune system and to lead to sustained HIV-1 
replication. First, the addition of the SCID mutation into the nonobese diabetic strain 
(NOD/SCID), which lacks the IL-2 receptor -chain, resulted in mice without T, B, and NK 
cells. With the implantation of human CD34+ hematopoietic stem cells into these mice, they 
developed human lymphocytes and dendritic cells in the blood and in multiple lymphoid 
tissues. Thus, HIV-1 infection could be sustained at high levels for more than 40 days 
(Watanabe et al., 2007). Similarly, transplantation of human fetal bone marrow (containing 
CD34+ cells), liver, and thymus (BLT) into NOD/SCID mice could also generate functional 
human T, B, and dendritic cells in both the periphery and tissues. These animals could 
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stably maintain HIV-1 replication after intrarectal or intravaginal challenge (Denton et al., 
2008; Sun et al., 2007). However, NOD/SCID mice develop thymic lymphomas, resulting in 
a limited lifespan (Shultz et al., 1995). 
Another humanized mouse model utilizes Rag2-/-C-/- double knockout mice, which also 
lack T, B, and NK cells. These mice can also be reconstituted with CD34+ hematopoietic stem 
cells, leading to development of human T, B, and dendritic cells in the blood and different 
lymphoid tissues (Traggiai et al., 2004). The animals could be infected with HIV-1 and had 
detectable viremia for more than 27 weeks (Baenziger et al., 2006). Like the BLT model, 
Rag2-/-C-/- mice also had CD4+ target cells in mucosal tissues and could be infected 
intrarectally or intravaginally (Berges et al., 2008).  
 
Macaques Humanized CD34+ reconstituted mice 
Advantages Disadvantages Advantages Disadvantages 
Similar viral 
pathogenesis to 
humans 
Genetically different 
than humans 
Target cells are 
human 
Lack of macro-
phages (Rag2/C-/-) 
and robust anti-
retroviral immunity 
Similar antiviral 
immune responses to 
humans 
Requires SIV or SHIV Can use different 
HIV-1 strains 
Small tissue/blood 
samples 
Long-term viral 
persistence during 
suppressive anti-
retroviral therapy 
Expensive and 
requires trained 
veterinary staff 
Can create genetic-
ally identical animals 
with cells from same 
donor 
Requires access to 
donor tissues and 
ability to perform 
transplants 
Access to large 
tissue/blood samples
Large size requiring 
more drugs 
Less overall cost Anatomically diff-
erent than humans 
Longer lifespan  Small size allows the 
use of less drugs 
Limited lifespan, 
especially BLT 
Table 1. Advantages and disadvantages to simian and murine models of HIV/AIDS 
2.3 What virus should be used with which model? 
With a wide array of simian and murine models of HIV/AIDS, it is difficult to know which 
one to use to answer a scientific question. Each model has its advantages and disadvantages 
(Table 1). Depending on the question, one has to weigh the pros and cons that may affect the 
results in deciding which model and which virus to employ. For example, macaques are 
more anatomically similar to humans and studying drug penetration into tissues or 
inhibition of virus in tissues, such as microbicides, may be more relevant in the monkey 
model. However, at this time HIV-1 replication is very limited in simians, necessitating the 
use of SIV or SHIVs. Therefore, drugs targeting viral proteins or virus-host cell protein 
interactions may be limited with these viruses and may require the use of HIV-1 in mice. 
Although mice are smaller and cheaper than monkeys, humanized murine models require 
significant expertise and human donors for tissue implantation and stem cell reconstitution 
that may not be more cost-effective for the investigator. The rest of the chapter will discuss 
the use of both simian and murine models for preclinical studies of anti-HIV therapies. 
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3. Therapy for HIV-1 prevention in animal models 
As there is no cure for HIV-1 yet, efforts have been made to develop and evaluate 
compounds that would prevent HIV-1 infection prior to or immediately after exposure to 
the virus. These differ from vaccines in that they are not designed to elicit antiviral 
immunity in advance of exposure, but rather would inhibit the virus before, during, or just 
after exposure to HIV-1 to avoid systemic infection. Pre-exposure prophylaxis would be 
initiated in high-risk individuals likely to be exposed to HIV-1, whereas post-exposure 
prophylaxis would be used in individuals who were believed to be recently exposed to the 
virus. Animal models have been used rather extensively over the past decade in this area of 
research with generally positive results. Unlike in clinical trials, the timing and adherence of 
treatment and the timing of virus challenge can be controlled in the model. 
3.1 Pre-exposure prophylaxis 
The majority of prevention therapy studies have focused on pre-exposure prophylaxis, or 
microbicides, against mucosal transmission of virus. This is particularly relevant in areas of 
the world where people, especially women, often are unable to control their partners’ use of 
condoms during sexual intercourse. Thus, a compound that can be applied mucosally or 
taken orally could inhibit HIV-1 infection either by targeting the virus or targeting viral 
interaction with host cell factors necessary for viral replication. 
3.1.1 Toxicity of mucosal drug application 
Generally, compounds that inhibit HIV-1 are discovered and characterized in vitro. Before 
going to clinical trials for efficacy testing, tolerability and toxicity studies in animals or 
people are often performed. In the case of topically applied microbicides, this entails 
determining whether a drug causes disruption of the mucosal epithelial layer that forms an 
intact barrier against incoming pathogens. The need for toxicity testing was made 
dramatically clear in the case of nonoxynol-9 (N-9), which was halted in clinical trials as a 
potential anti-HIV topical microbicide due to toxic effects that made users more susceptible 
to HIV-1 infection. N-9, a nonionic detergent present in some contraceptive gels, was shown 
long ago to inhibit viral replication in vitro (Hicks et al., 1985). Several clinical studies of N-9 
use in women during vaginal sexual intercourse suggested that it slightly increased the risk 
for HIV-1 seroconversion (Wilkinson et al., 2002). There were discrepancies on whether or 
not N-9 caused toxicity in the female genital tract, which may have been due to poor 
adherence and inappropriate application of the product. A careful study in the pigtailed 
macaque model showed that N-9 caused genital tissue damage (Patton et al., 1999). 
The female genital tract consists of stratified squamous epithelial cells (vagina and 
ectocervix) and simple columnar epithelium (endocervix), while the GI tract consists only of 
a single layer of columnar epithelial cells. Trials of N-9 for rectal use showed that histological 
abnormalities occurred in almost 90% of the subjects (Tabet et al., 1999) and caused rapid 
exfoliation of the rectal epithelium (Phillips et al., 2000). Similar results were also observed 
in pigtailed macaques (Patton et al., 2002), suggesting that safety testing is necessary for 
microbicides prior to initiating clinical studies to prevent enhanced HIV-1 transmission. 
Inflammation and toxicity markers and their correlation, or lack thereof, with complete 
protection from transmission are still incompletely defined. Administration of a foreign 
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compound is likely to induce innate immune responses. This is also the initial response of 
the body in countering HIV-1 immediately following exposure. Maintaining normal, intact 
tissue and normal microflora at mucosal sites during use of a topical microbicide will 
continue to be a challenge. And the use of oral drugs that can penetrate tissues also will 
need to be evaluated for safety and lack of mucosal toxicity. 
3.1.2 Therapeutic prevention studies 
Many compounds have been tested as pre-exposure prophylaxis in animal models prior to 
intravaginal, intrarectal, or oral exposure of virus. Such preventive drugs can be nonspecific 
to HIV-1 or specific antiretroviral compounds. Intravaginal or intrarectal transmission of 
HIV-1 occurs during sexual contact, while oral transmission may contribute to infection of 
infants during vaginal delivery. While both macaque and humanized mouse models have 
been useful for mucosal viral transmission, HIV-1 can only be used to infect humanized 
mice. Macaques can be infected effectively with chimeric SHIV viruses containing HIV-1 
envelope or RT.  And the anatomy of nonhuman primates, including the gastrointestinal 
and genital tracts, is more similar to that of humans. 
The majority of such pre-exposure prophylaxis studies have been performed with various 
levels of success in female macaques for the prevention of vaginal transmission. 
Compounds tested in macaque models have aimed to interfere with nonspecific viral 
attachment (Ambrose et al., 2008; Boadi et al., 2005; Kenney et al., 2011; Kim et al., 2006; 
Lagenaur et al., 2011; Li et al., 2009; Manson et al., 2000; Tevi-Benissan et al., 2000; Tsai et al., 
2004; Wyand et al., 1999), specific interactions of envelope with receptor/co-receptors (Kish-
Catalone et al., 2007; Lederman et al., 2004; Mascola et al., 2000; Parren et al., 2001; Veazey et 
al., 2008; Veazey et al., 2010; Veazey et al., 2003a; Veazey et al., 2005a; Veazey et al., 2009; 
Veazey et al., 2003b; Veazey et al., 2005b), and reverse transcription (Kenney et al., 2011; 
Parikh et al., 2009; Stolte-Leeb et al., 2011; Turville et al., 2008). Another study investigated 
hormone treatment, which leads to thickening of the vaginal epithelium, to prevent vaginal 
transmission of SIV in macaques (Smith et al., 2000b). More recently, the humanized mouse 
model has been used to prevent intravaginal transmission, using drugs targeting RT 
(Denton et al., 2008; Denton et al., 2011), integrase (Neff et al., 2011a), the CCR5 co-receptor 
(Neff et al., 2011a; Neff et al., 2010), and viral protein expression (Wheeler et al., 2011).  
Fewer studies have evaluated compounds that prevent intrarectal or oral transmission of 
HIV-1 or SHIVs. The FDA-approved RT inhibitor tenofovir was successful in preventing 
intrarectal transmission of SIV in macaques (Cranage et al., 2008) and of HIV-1 in 
humanized mice (Denton et al., 2010). Also, a novel RT inhibitor (Singer et al., 2011) and a  
nonspecific envelope attachment inhibitor (Tsai et al., 2003) were used to prevent intrarectal 
transmission of SHIVs in macaques. For prevention of oral viral transmission, only macaque 
models have been used. First, neutralizing antibodies were shown to be protective in 
neonates (Baba et al., 2000). More recently, subcutanously administered tenofovir was found 
to be somewhat protective against oral SIV challenge (Van Rompay et al., 2006; Van Rompay 
et al., 2001) while an oral tenofovir solution was ineffective (Van Rompay et al., 2006; Van 
Rompay et al., 2002b).  
While most of these studies have focused on topical gels and novel compounds, oral FDA-
approved antiretroviral compounds have been investigated recently as pre-exposure 
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prophylaxis. Tenofovir prevents HIV-1 replication, it is already approved for use in humans 
in the oral formulation, and high drug concentrations can be achieved in the male and 
female genital tracts (Kwara et al., 2008; Vourvahis et al., 2008). The use of a gel may not 
provide complete coverage of the mucosal surface, possibly leading to breakthrough 
infections. The CAPRISA 004 clinical trial recently showed a 39% overall reduction in HIV-1 
incidence in women using a vaginal tenofovir gel (Abdool Karim et al., 2010). The iPrEx and 
TDF2 trials showed that oral tenofovir in combination with another RT inhibitor, 
emtracitabine (FTC), reduced transmission in men who have sex with men (Grant et al., 
2010) or in heterosexual men and women (Roehr, 2011) by 44% and 63%, respectively. It is 
unclear whether the greater efficacy in the latter studies as compared to the CAPRISA 004 
study was due to oral administration of drug or use of two drugs instead of tenofovir alone. 
In macaques, intermittent dosing (2 hours before and 24 hours after challenge) of tenofovir 
alone or with FTC was equally as effective as daily dosing during weekly repeated low-dose 
rectal challenges (Garcia-Lerma et al., 2008). Less frequent doses would reduce cost to the user 
and would not require strict daily adherence. However, breakthrough infections in 2 of 6 
animals resulted in drug resistant viruses, which could potentially compromise future therapy. 
Interestingly, with the exception of tenofovir or tenofovir/FTC, no other microbicides have 
been successful in the clinic. It remains to be seen whether or not this is due to a specific 
property of tenofovir or RT inhibitors in general. Tenofovir acts specifically on viral reverse 
transcription, whereas most other microbicides tested clinically were nonspecific entry 
inhibitors. Also, tenofovir is the only drug that has been tested with repeated low-dose SIV 
oral, intravaginal, and intrarectal challenges in macaques (Garcia-Lerma et al., 2008; Parikh 
et al., 2009; Van Rompay et al., 2006). A nonspecific virus inactivating compound was tested 
in repeated high-dose intravaginal challenges 10-47 weeks apart, in which 90% of the 
animals were protected after the initial challenge (Ambrose et al., 2008). However, nearly all 
the animals became infected after the second challenge. It is unclear if noninfectious virus at 
the site of transmission elicits a detrimental immune response, inflammation, and/or an 
increase in target cells that can cause a subject to become more sensitized to infection. 
Until recently, mucosal challenge of SIV or SHIV required high doses of virus to ensure that 
all or most of the control animals become infected. More and more investigators are using 
repeated low-dose challenges in animal studies to recapitulate more realistic levels of virus 
detected in semen of untreated HIV+ men. Semen viral RNA levels are often similar to or 
lower than in the blood (Gupta et al., 1997; Liuzzi et al., 1996), but are significantly lower 
than those of laboratory stocks used in high-dose challenges (Marthas et al., 2001). Also, 
high-risk individuals may be exposed multiple times prior to becoming infected. A direct 
comparison of a high-dose challenge and repeated low-dose rectal challenges in a small 
study on oral tenofovir pre-exposure prophylaxis showed that the low-dose model was 
actually somewhat more stringent (Subbarao et al., 2007). The disadvantage of the low-dose 
model is that multiple challenges are required to infect untreated control monkeys, and this 
number varies significantly among animals. This can affect statistics and often leads to 
longer experiments, which can increase study costs. 
3.2 Post-exposure prophylaxis  
Most post-exposure prophylaxis research has focused on entry and reverse transcription 
inhibitors that target the earliest steps of HIV-1 replication. Tenofovir was the first 
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successful drug used for post-exposure treatment in the macaque model against intravenous 
challenge of SIV (Tsai et al., 1995). Animals did not become infected when daily tenofovir 
treatment was initiated 4 or 24 hours post-challenge, continuing for 4 weeks. A similar study 
with AZT did not show protection 3 hours after intravenous SIV inoculation (Fazely et al., 
1991). Later, vaginal transmission was largely prevented in macaques after tenofovir 
treatment began 12 or 36 hours post-challenge but not after 72 hours (Otten et al., 2000).   
The other post-exposure prophylaxis method used in the macaque model has been passive 
transfer of neutralizing antibodies targeting HIV-1 envelope. Antibody transfer into 
macaques 6 hours post-infection with SHIV showed 75% protection, which declined to 50% 
after 24 hours (Nishimura et al., 2003). Multiple monoclonal antibodies were more 
successful than an individual antibody. Complete protection was also seen after antibody 
infusion 1 hour after oral SHIV challenge of neonates, which decreased after 12 or 24 hours 
(Ferrantelli et al., 2004).  
While these post-exposure prophylaxis studies showed promise, highly pathogenic viruses 
may be more difficult to control. One study showed that a combination of neutralizing 
antibodies given to neonates at 1 hour and 8 days post-challenge led to 100% protection in 
animals infected with a SHIV, but did not protect animals from a more pathogenic virus 
(Hofmann-Lehmann et al., 2001). This same highly pathogenic virus also failed to be 
controlled by triple therapy of AZT, 3TC, and the protease inhibitor indinavir when initiated 
4 hours after intravenous infection and continued for 14-28 days (Bourry et al., 2009; Le 
Grand et al., 2000). These studies noted that although most of the animals became infected, 
plasma viremia was reduced compared to the control animals, suggesting a partial 
protective effect of the treatment regimens. 
3.3 Mother-to-child transmission prevention 
Mother-to-child transmission (MTCT) of HIV-1 occurs via three mechanisms: in utero via 
virus transfer across the placenta, intrapartum presumably by oral inoculation of the 
infected mother’s blood, and breastfeeding. An early clinical trial showed that AZT therapy 
of HIV-infected women during pregnancy and of infants in the first 6 weeks after birth led 
to a 67.5% reduction in MTCT (Connor et al., 1994).  
In resource-rich nations, combination therapy is now the standard of care for pregnant 
women. However, the cost of multiple drugs and/or multiple doses of drugs poses a 
challenge in resource-limited countries. Thus, studies were conducted in which single doses 
of nevirapine were administered to women during labor (and sometimes to the infant) to 
prevent MTCT. Nevirapine, a non-nucleoside RT inhibitor, has less toxicity than AZT and 
has a long half-life (Musoke et al., 1999). Single-dose nevirapine treatment effectively 
reduced HIV-1 MTCT to a similar degree as multiple doses of AZT (Guay et al., 1999). 
Unfortunately, it was revealed that single-dose nevirapine caused the development of drug-
resistant virus in the mothers and in infants that subsequently became infected (Eshleman et 
al., 2001), which could be present at low frequencies for long periods of time (Flys et al., 
2005; Palmer et al., 2006). Such drug resistance compromised subsequent treatment in the 
mothers (Jourdain et al., 2004).  
Few studies on MTCT have been performed in animal models. One study using a pregnant 
macaque model of MTCT showed that short-term combination therapy could successfully 
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prevent in utero transmission of HIV-2 to the fetus/infant (Ho et al., 2000). SIV transmission 
in nonhuman primates via breastfeeding has been demonstrated and used to study 
tenofovir pharmacokinetics in breast milk (Van Rompay et al., 2005). However, this model 
has not be used in any therapeutic prevention studies. Oral inoculation macaque models 
have been used to study pre-exposure and post-exposure prophylaxis, as discussed above.  
It appears that the first few hours after virus exposure is critical for using therapy to stop 
infection. This is important to minimize the spread of virus to new target cells. While most 
research has focused on a single inhibitor or class of inhibitors, it remains to be seen if drug 
combinations will afford more time to an exposed individual to prevent fulminant infection. 
Treatment of adults and infants, even when initiated immediately after exposure, may be 
ineffective if they have been exposed to drug-resistant or highly pathogenic viruses. This 
could be alleviated with combination therapy. Also, post-exposure treatment has generally 
been administered daily for 4 weeks. To save money and to avoid prolonged side effects 
from the drugs, can the duration of therapy be shortened and remain effective? Finally, will 
breakthrough infections result in selection of drug-resistant viruses, which could lead to 
virologic failure during subsequent antiretroviral treatment? 
4. Animal models for new suppressive antiretrovirals, combinations, and 
deliveries 
Animal models for antiretroviral research can be used to test novel compounds for their 
toxic properties, pharmacokinetics and bioavailability, and antiretroviral efficacy. 
4.1 Toxicity, pharmacokinetics, tissue distribution 
While it is impossible to document or list all antiretroviral pharmacokinetics and toxicity 
research in animals here, a few examples of early and new studies should be noted. 
Nucleoside analogs that inhibit reverse transcription, such as ddC (Kelley et al., 1987) and 
d4T (Keller et al., 1995), were tested in mice and monkeys for toxicity and pharmacokinetics. 
The short-term and long-term effects of tenofovir in newborn/infant macaques showed 
bone and kidney toxicities (Van Rompay et al., 2004). Also, non-nucleoside RT inhibitors, 
such as efavirenz, were tested in animals for pharmacokinetics (Balani et al., 1999). 
Investigators also developed drugs to the other HIV-1 enzymes: protease and integrase. 
While many of the protease inhibitors had poor efficacy against SIV, their pharmacokinetics 
could be assessed in animals, such as that of nelfinavir (Kaldor et al., 1997). Many integrase 
inhibitors were screened by Merck, leading to testing of many potential new compounds for 
good bioavailability in nonhuman primates and mice (Gardelli et al., 2007; Pace et al., 2007). 
Even HIV-1 entry inhibitors, such as SCH-D, which would later be named vicriviroc, were 
tested in mice and monkeys for general pharmacokinetics (Tagat et al., 2004). Also, 
maraviroc was studied for intrapartum pharmacokinetics and dynamics in pregnant 
macaques as a potential method to prevent MTCT (Winters et al., 2010). 
4.2 Efficacy in viral inhibition 
The virus and model used to test antiretroviral drug efficacy are dependent on the drug 
target. For example, due to sequence differences in the Gag protein, the maturation inhibitor 
bevirimat does not inhibit SIV (Zhou et al., 2004). Therefore, proof of concept in vivo studies 
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were performed in a humanized mouse model to show drug inhibition against HIV-1 
(Stoddart et al., 2007). Similarly, testing of a CCR5 inhibitor like maraviroc is best used with 
HIV-1 envelope. Therefore, nonhuman primate studies were performed with SHIV virus 
containing a CCR5-tropic envelope (Veazey et al., 2003a). 
Many novel antiretroviral small molecule inhibitors have been characterized for efficacy 
against HIV, SIV, or SHIV in animal models, many leading to FDA approval or to more 
improved versions of the compounds (reviewed in Ambrose and KewalRamani, 2008; Van 
Rompay, 2010). For example, PMEA, a drug related to tenofovir, was found to inhibit SIV 
infection effectively in macaques (Balzarini et al., 1991). Unfortunately, PMEA was very 
toxic in vivo, which lead to the development of the related and less-toxic compound 
tenofovir (previously called PMPA), which has been studied extensively in monkeys for 
viral inhibition (Balzarini et al., 1991; Lifson et al., 2003; Smith et al., 2000a; Tsai et al., 1998). 
Another RT inhibitor, stavudine, was tested for antiretroviral properties in HIV-2-infected 
macaques (Watson et al., 1997). And after many years of screening compounds in vitro, a 
precursor to the first FDA-approved integrase inhibitor, raltegravir, was shown to be 
effective in viral inhibition in the macaque model (Hazuda et al., 2004).  
While many exciting novel antiretroviral inhibitors are currently under investigation in in 
vitro models, general efficacy testing is not always performed in an animal model prior to 
clinical studies. This is due to the high costs associated with these experiments, particularly 
in macaques and humanized mice. The major advantage of an animal model is the ability to 
perform procedures that may exacerbate disease or that are highly invasive. These may not 
be ethical or easy to perform in humans. For example, treatment interruptions or intentional 
induction of drug resistance is likely to be harmful to an HIV-infected individual. However, 
understanding the effects of these procedures can lead to a better understanding of the 
development of drug resistance and its effects on subsequent treatment regimens. Also, 
obtaining organs, longitudinal blood or tissue samples, and specific time points after 
infection or therapy initiation cannot be acquired easily in people.  
4.3 Drug resistance 
Drug resistance in HIV-infected individuals arises from inadequate therapy, which could be 
the result of ineffective prescribed therapy or nonadherence. While most data on HIV-1 
drug resistance have been obtained from clinical studies, the macaque model has been used 
to address various questions on the development and consequences of drug-resistant virus.  
Because nucleoside analogs such as tenofovir and FTC inhibit SIV and have good 
pharmacokinetics in macaques, mutations to these drugs have been studied in the monkey 
model. The primary resistance mutation to FTC has been studied for its effects on in vivo 
viral virulence and fitness (Van Rompay et al., 2002a). Similarly, mutations conferring 
resistance to tenofovir were studied in SIV for their emergence and suppression in vivo 
during tenofovir monotherapy (Van Rompay et al., 2007). Resistant viruses were identified 
in macaques with breakthrough infections after intermittent tenofovir/FTC pre-exposure 
prophylaxis with intrarectal challenge (Garcia-Lerma et al., 2008). And FTC- and tenofovir-
resistant SHIV mutants were created and tested for their mucosal transmissibility (Cong et 
al., 2011), presumably to determine the effects of tenofovir and FTC pre-exposure 
prophylaxis on transmitted drug-resistant virus. 
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RT-SHIVs were created to study non-nucleoside RT inhibitors, such as efavirenz, that are 
specific to HIV-1 but not to HIV-2 or SIV. Efavirenz monotherapy leads to the emergence of 
common resistance mutations that are seen in patients (Ambrose et al., 2007; Hofman et al., 
2004). Efavirenz combined with tenofovir and FTC is a commonly prescribed combination 
therapy for HIV-infected individuals and was shown to be effective in reducing RT-SHIV 
plasma viremia in two species of macaques (Ambrose et al., 2007; North et al., 2005). Prior 
efavirenz resistance was shown to compromise combination therapy in one animal, leading 
to accumulation of FTC-resistant mutations in the virus and, ultimately, failure of therapy 
(Ambrose et al., 2007). This was similar to results described earlier in the single-dose 
nevirapine trials for prevention of MTCT. In addition, the RT-SHIV model allowed the 
study of viral subpopulation dynamics in animals, including those of drug-resistant viral 
variants (Shao et al., 2009). 
While resistance to clinically used antiretrovirals, such as FTC, tenofovir, and efavirenz, are 
well documented, compounds for pre-exposure prophylaxis have also been evaluated in 
vivo for the ability to select for drug-resistant viruses. As stated earlier, breakthrough 
infections after FTC and tenofovir prophylaxis was demonstrated in macaques (Garcia-
Lerma et al., 2008). Similarly, mutations in the SHIV envelope were observed in virus from a 
macaque after ineffective use of the topical entry inhibitor PSC-RANTES that conferred little 
or no resistance to the compound (Dudley et al., 2009). Monitoring of potential drug-
resistant virus is critical in preclinical and clinical studies with new inhibitors, as resistance 
may negatively impact efficacy of future treatment regimens. 
4.4 New delivery methods 
One complication of HIV-1 infection is the presence of large numbers of infected cells within 
different tissues. Although discussed more in the next section, CD4+ target cells are present 
within lymphoid tissues, the brain, and multiple mucosal tissues. Drug penetration into 
these tissues is likely to be lower than in the blood, allowing viral replication to continue 
within tissues. Research on better drug delivery methods into different tissues has been 
ongoing. This will be especially important for methods to target drugs into mucosal tissues 
during pre-exposure prophylaxis and also persisting viral reservoirs.  
While there may be many novel delivery methods in the pipeline, only a few have been 
tested in vivo to specifically prevent transmission of or reduce replication of HIV-1/2. One 
novel delivery method of antiretrovirals to tissues is the formation and administration of 
drug nanocomplexes. A protease inhibitor, indinavir, was formed into nanoparticles and 
delivered to HIV-2-infected macaques, leading to significantly increased lymph node 
lymphocyte drug concentrations as compared to animals given the drug orally (Kinman et 
al., 2003). Nanoparticles are often cleared from the blood and tissues by phagocytic cells, 
such as macrophages. As macrophages are infected by HIV-1, these cells have been 
proposed as a target for drug delivery and phagocytosis of drug by infected cells may be 
beneficial. A single intravenous dose of indinavir-containing nanoparticles in mice with 
HIV+ brain macrophages led to drug levels in the brain for up to 14 days and reduced virus 
replication in the brain (Dou et al., 2009). Nevertheless, optimization of nanocomplexes by 
coating their surfaces with polyethylene glycol resulted in sustained levels in the blood of 
mice and less clearing by macrophages (Levchenko et al., 2002).  
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Another newly developed technology is the silencing of protein expression by small 
interfering RNAs (siRNA). siRNA can be designed to target specific mRNA in cells for 
degradation, leading to loss of protein expression (Hammond et al., 2000; Zamore et al., 
2000). Because siRNA can be designed specifically to silence almost any RNA, they have 
been proposed for treatment of various diseases, including HIV-1 infection. However, 
targeting siRNA to specific cell types, to infected cells, and into tissues has been challenging, 
as they do not easily cross the plasma membrane and are quickly degraded by nucleases. 
Therefore, different delivery methods have been explored for more optimal targeting of siRNA 
to HIV-infected cells. For example, siRNA were bound to an antibody fragment that 
recognized HIV-1 envelope. These antibody-siRNA molecules were able to specifically target 
and enter envelope-expressing cells in mice (Song et al., 2005). And many techniques for 
introducing siRNA into nanoparticles have been tested for better pharmacokinetics, but these 
have been mainly preclinical studies not involving HIV-1 (reviewed in Yuan et al., 2011). 
More recently, another method of delivering siRNA has been tested in both humanized mouse 
models to inhibit HIV-1 infection. RNA aptamer-siRNA chimeras were generated such that the 
aptamer portion would selectively bind to a cell surface molecule, delivering the siRNA to 
target cells (McNamara et al., 2006). RNA aptamers are oligonucleotides that are designed to 
bind tightly to specific proteins (Ellington and Szostak, 1990; Tuerk and Gold, 1990). One 
group used a mixture of chimeric RNAs with a CD4-binding aptamer and with siRNA 
targeting mRNA encoding the HIV-1 co-receptor CCR5 and viral proteins as a topical vaginal 
microbicide in BLT mice (Wheeler et al., 2011). The drug was able reduce CCR5 expression in 
vivo and resulted in a significant reduction of virus transmission. Another group used chimeric 
RNAs with HIV-1 envelope-binding aptamers and siRNA targeting multiple HIV-1 mRNA 
(Neff et al., 2011b). They were injected into HIV-1-infected Rag2-/-C-/- humanized mice, 
leading to a significant reduction of both plasma viremia and CD4+ cell depletion.  
The development of novel drugs and drug delivery methods is important for HIV-1 
research. First, toxicity and adverse side effects of existing antiretrovirals are not trivial and 
should be improved to promote better adherence. Second, a lack of adherence will lead to 
drug resistance, which can affect multiple available treatment regimens. Third, improved 
prevention strategies will be necessary in the absence of a cure and in curbing the spread of 
HIV-1 infection among high-risk individuals. Lastly, as discussed below, targeting of new 
drugs to tissues to eliminate infected cells is an exciting possibility only recently realized. 
5. Animal models for targeting persisting viral reservoirs 
There is no cure for HIV-1. While HIV-infected individuals can suppress plasma viremia to 
undetectable levels with effective therapy, infected cells remain in the body and virus will 
return to the blood if therapy is halted or drug-resistance arises. The cells and tissues that 
harbor proviral DNA are considered viral reservoirs and are not completely characterized. 
Animal models allow investigators to more easily evaluate where infected cells are located 
and how to eradicate them than in humans.  
5.1 Evaluating viral reservoirs during antiretroviral therapy 
Because antiretroviral drugs were designed to target HIV-1, some of them are inefficient or 
unable to suppress SIV replication. In an animal model, antiretroviral suppression should be 
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as good as what is observed in humans on combination antiretroviral therapy. Standard 
assays detect down to 50 copies of viral RNA per milliliter of plasma, but even with typical 
three drug regimens it has been difficult to completely inhibit plasma viremia in some 
macaques to undetectable levels (Ambrose et al., 2007; Dinoso et al., 2009; Lugli et al., 2011; 
North et al., 2005). The ability to achieve complete suppression generally correlates with the 
level of plasma viremia prior to treatment, such that higher viral loads are more difficult to 
completely suppress (Kearney et al., 2011). In mouse models, combination therapy has only 
been evaluated in humanized Rag2-/-C-/- mice, which also showed incomplete viral 
suppression (Choudhary et al., 2009; Sango et al., 2010). These results may be due to reduced 
efficacy against SIV proteins and/or different drug pharmacokinetics in macaques or mice 
as compared to humans. 
In identifying and characterizing persistent viral reservoirs in an animal model, complete 
and sustained suppression is necessary. Recent reports suggest that ongoing viral 
replication does not occur during suppressive therapy in humans, based on a lack of viral 
evolution (Bailey et al., 2006; Kieffer et al., 2004; Nottet et al., 2009; Persaud et al., 2007). This 
was also observed in RT-SHIV-infected monkeys with sustained plasma virus suppression 
(Kearney et al., 2011). Continued virus replication in the presence of incomplete suppression 
will lead to infection of new target cells and re-seeding of reservoirs, which will interfere 
with identification of the actual reservoir that was established prior to initiation of therapy. 
This is especially important when looking at the reduction of infected cells by virus 
eradication therapies, as discussed below. 
Despite the lack of complete suppression in many animals, the macaque model has been 
used to try to identify and characterize viral reservoirs. In an SIV model with FTC and 
tenofovir therapy, it was shown that resting CD4+ T lymphocytes from lymph nodes but not 
thymocytes contribute to the reservoir (Shen et al., 2003). While viral DNA was detected in 
multiple tissues of RT-SHIV-infected animals with and without triple therapy, very little or 
no viral RNA was detected in these tissues during complete suppression (North et al., 2010; 
Ambrose et al., unpublished results). Lymphoid and gastrointestinal tissues showed the 
highest level of viral DNA in virally suppressed animals, suggesting that they consist of the 
majority of the viral reservoir. In a model of neuropathogenic AIDS, although viremia in 
plasma and cerebral spinal fluid was significantly reduced by therapy, levels of viral DNA 
in the brains of these animals were not significantly different than the untreated controls, 
suggesting that virally infected cells in the central nervous system can contribute to the 
reservoir (Zink et al., 2010).  
5.2 Preliminary studies using animal models for eradication strategies 
To target persisting HIV-infected cells with therapeutic drugs for their eradication, one 
needs to know where the reservoirs are located and what types of cells are infected. While 
more research needs to be performed to address the type and location of infected CD4+ cells 
that persist and if these vary at different anatomical locations, investigators are already 
testing novel therapies to selectively target infected cells.   
The majority of these strategies aim to stimulate latently infected, resting CD4+ cells during 
suppressive antiretroviral therapy. The purpose is to promote replication of virus in those 
cells without causing global immune activation and without leading to spread of infection to 
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new cells. Histone deacetylase (HDAC) inhibitors and phorbol esters that stimulate protein 
kinase C (PKC) have received attention for their ability to activate latent HIV-1 expression in 
vitro (Colin and Van Lint, 2009). Clinical studies showed little or no decrease in latently 
infected cells or vDNA in most subjects by administration of a FDA-approved HDAC 
inhibitor, valproic acid, in the presence of suppressive ART (Archin et al., 2008; Sagot-
Lerolle et al., 2008; Siliciano et al., 2007). This is most likely to be a result of incorrect 
HDAC(s) targeting and/or inadequate drug concentrations (Huber et al., 2011; Keedy et al., 
2009). 
Animal models will be useful to test efficacy and mechanisms of action of potential 
therapies to eliminate infected cells from the body. Very recently a few studies have 
described the use of novel strategies in vivo and ex vivo to target viral reservoirs. Lipid 
nanoparticles containing the PKC activator bryostatin minimally induced proviral 
expression from infected CD4+ cells isolated from SCID-hu mice with thymus/liver 
implants (Kovochich et al., 2011). Also, a gold-based compound, auranofin, was used to 
treat SIV-infected macaques already receiving triple therapy (Lewis et al., 2011). After a 
month of treatment, PBMC proviral DNA levels decreased in the animals and plasma viral 
RNA was reduced after interruption of treatment. 
While new eradication treatments are promising for reducing or eliminating viral reservoirs, 
there are many issues and remaining questions that need to be addressed. First, an 
assumption is that latently infected cells will die after they are activated. However, to date 
this has not been demonstrated in animals or in people. And it remains to be seen if there 
are strategies that can selectively activate HIV- or SIV-infected cells but not uninfected cells. 
Second, it is important to identify models or treatment options that can achieve complete, 
sustained virus suppression as is observed in patients. If this is achieved, methods to 
measure decreases in viral reservoirs will need to be optimized, including assays to measure 
a single copy of plasma viral RNA, a single infected cell, and spliced vs. unspliced viral 
RNA. 
Finally, there are two caveats to the mouse and macaque models for studying persisting 
viral reservoirs. While mice can be rather effectively repopulated with a largely functional 
immune system, their anatomy is largely different than that of humans. Identification of 
reservoirs in mice will need to be confirmed with what is already known in humans. And 
although monkeys are more similar anatomically to humans, HIV-1 replication is not 
maintained in these animals. It remains to be seen whether transcriptional activation of SIV 
is similar to or different than that of HIV-1. Compounds designed to target activation of the 
HIV-1 LTR may not work or may work differently against SIV LTRs. Characterization of the 
various models for investigation of virus reservoirs should, therefore, continue. 
6. Conclusion 
This chapter has highlighted the use of macaque and mouse models for antiretroviral 
therapies. These animal models have improved greatly since the development of SHIVs and 
the ability to reconstitute a functional human immune system in mice. Refinement of these 
models is ongoing to make them more closely resemble humans with regards to infection, 
pathogenesis, and antiretroviral immunity. For example, macaque models can be improved 
by increased understanding of macaque cell proteins that inhibit HIV-1 infection as well as 
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the genetic differences between HIV-1 and SIV, particularly the accessory proteins that 
appear to significantly contribute to pathogenesis. Not only will these findings make a better 
animal model, but virus-host cell protein interactions characterized by these studies may 
also lead to new therapeutic targets. Also, alterations of the current humanized mouse 
models to improve tissue immune cell reconstitution and anti-HIV adaptive immune 
responses will better recapitulate HIV-1 infection of humans. 
While much work has been accomplished in HIV-1 research, questions remain for pre- and 
post-exposure prophylaxis, antiretroviral pharmacokinetics and efficacy, drug resistance, 
new drug delivery technologies, and methods for virus eradication. Using the models 
described here can help answer many of these questions, if used appropriately. Animal 
models continue to improve therapeutics against HIV-1 and they will be critical for 
addressing these important issues, bridging basic research together with clinical trials for 
HIV-1 prevention, treatment, and eradication. 
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